Correction: Kovanda, L., et al. In Vitro Antimicrobial Activities of Organic Acids and Their Derivatives on Several Species of Gram-Negative and Gram-Positive Bacteria. Molecules 2019, 24, 3770

Autor: Lauren Kovanda, Wen Zhang, Xiaohong Wei, Jia Luo, Xixi Wu, Edward Robert Atwill, Stefan Vaessen, Xunde Li, Yanhong Liu

Publikováno v: Molecules, Vol 25, Iss 12, p 2787 (2020)

The authors wish to make the following corrections to this paper published in Molecules [...]

Externí odkaz: https://doaj.org/article/68c868ea34f3480b92d637f8116b0117

Correction: Kovanda, L., et al. In Vitro Antimicrobial Activities of Organic Acids and Their Derivatives on Several Species of Gram-Negative and Gram-Positive Bacteria. Molecules 2019, 24, 3770

Autor: Wen Zhang, Xiaohong Wei, Yanhong Liu, Jia Luo, Xunde Li, Stefan Vaessen, Xixi Wu, Lauren Kovanda, Edward R. Atwill

Publikováno v: Molecules
Molecules, Vol 25, Iss 2787, p 2787 (2020)

The objective of this study was to determine the in vitro antimicrobial activity of several organic acids and their derivatives against Gram-positive (G+) and Gram-negative (G-) bacteria. Butyric acid, valeric acid, monopropionin, monobutyrin, monova

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::864ee4bed1267bbb65f21fee0c18f9c4
https://doi.org/10.3390/molecules25122787

Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2022) 4190-4198].

Autor: Chichili GR; Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, United States. Electronic address: gurunadh.chichili@astellas.com., Smulders R; Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, United States., Santos V; Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, United States., Cywin B; Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, United States., Kovanda L; Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, United States., Van Sant C; Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL 60062, United States., Malinoski F; Affinivax, 301 Binney St, Cambridge, MA 02142, United States., Sebastian S; Affinivax, 301 Binney St, Cambridge, MA 02142, United States., Siber G; Affinivax, 301 Binney St, Cambridge, MA 02142, United States., Malley R; Affinivax, 301 Binney St, Cambridge, MA 02142, United States.

Publikováno v: Vaccine [Vaccine] 2024 Oct 03; Vol. 42 (23), pp. 126023. Date of Electronic Publication: 2024 Jun 18.

Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.

Autor: Yasinskaya Y; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Bala S; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Waack U; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Dixon C; Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration ; Silver Spring, Maryland, USA., Higgins K; Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration ; Silver Spring, Maryland, USA., Moore JN; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration ; Silver Spring, Maryland, USA., Jjingo CJ; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., O'Shaughnessy E; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Colangelo P; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration ; Silver Spring, Maryland, USA., Botgros R; Health Threats and Vaccines Strategy, European Medicines Agency, Amsterdam, the Netherlands., Nambiar S; Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Angulo D; Scynexis, Jersey City, New Jersey, USA., Dane A; DaneStat Consulting, Macclesfield, United Kingdom., Chiller T; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Hodges MR; RNA Medicines, San Diego, California, USA., Sandison T; Cidara Therapeutics, San Diego, California, USA., Hope W; Centre for Excellence in Infectious Diseases Research, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Walsh TJ; Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine, New York, New York, USA., Pappas P; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA., Katragkou A; Transplantation-Oncology Infectious Disease Program, Weill Cornell Medicine, New York, New York, USA., Kovanda L; Astellas Pharma Global Development, Northbrook, Illinois, USA., Rex JH; F2G, Manchester, United Kingdom., Marr KA; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Ostrosky-Zeichner L; Director of the Laboratory of Mycology Research, McGovern Medical School, Houston, Texas, USA., Sekine S; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Deshpande M; DRT Strategies, Arlington, Virginia, USA., Shukla SJ; Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Farley J; Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Aug 14; Vol. 77 (3), pp. 380-387.

Dietary supplementation of botanical blends enhanced performance and disease resistance of weaned pigs experimentally infected with enterotoxigenic Escherichia coli F18.

Autor: Wong BT; Department of Animal Science, University of California, Davis, CA 95616, USA., Park S; Department of Animal Science, University of California, Davis, CA 95616, USA., Kovanda L; Department of Animal Science, University of California, Davis, CA 95616, USA., He Y; Department of Animal Science, University of California, Davis, CA 95616, USA., Kim K; Department of Animal Science, University of California, Davis, CA 95616, USA., Xu S; Department of Animal Science, University of California, Davis, CA 95616, USA., Lingga C; Department of Animal Science, University of California, Davis, CA 95616, USA., Hejna M; Department of Animal Science, University of California, Davis, CA 95616, USA.; Department of Health, Animal Science and Food Safety, Università degli Studi di Milano, Milan, Italy., Wall E; AVT Natural, Kerala, India., Sripathy R; AVT Natural, Kerala, India., Li X; Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, CA 95616, USA., Liu Y; Department of Animal Science, University of California, Davis, CA 95616, USA.

Publikováno v: Journal of animal science [J Anim Sci] 2022 Dec 01; Vol. 100 (12).